Wells Fargo & Company Raises West Pharmaceutical Services, Inc. (WST) Price Target to $112.00

West Pharmaceutical Services, Inc. (NYSE:WST) had its target price lifted by Wells Fargo & Company from $105.00 to $112.00 in a report released on Friday. Wells Fargo & Company currently has an outperform rating on the medical instruments supplier’s stock.

A number of other research firms have also issued reports on WST. Stephens began coverage on West Pharmaceutical Services in a research note on Tuesday, October 3rd. They issued an equal weight rating and a $99.00 target price on the stock. Bank of America Corporation lowered West Pharmaceutical Services from a buy rating to a neutral rating and set a $98.00 target price on the stock. in a research note on Tuesday, October 17th. Zacks Investment Research raised West Pharmaceutical Services from a sell rating to a hold rating in a research note on Wednesday, September 27th. BidaskClub lowered West Pharmaceutical Services from a buy rating to a hold rating in a research note on Wednesday, July 5th. Finally, Jefferies Group LLC raised West Pharmaceutical Services from a hold rating to a buy rating and upped their target price for the company from $96.00 to $115.00 in a research note on Friday, September 15th. One research analyst has rated the stock with a sell rating, three have given a hold rating and three have assigned a buy rating to the company. The company presently has an average rating of Hold and a consensus price target of $106.00.

West Pharmaceutical Services (NYSE:WST) opened at 101.16 on Friday. West Pharmaceutical Services has a 12 month low of $72.34 and a 12 month high of $103.36. The stock has a market cap of $7.49 billion, a P/E ratio of 43.42 and a beta of 1.12. The company’s 50-day moving average price is $94.50 and its 200-day moving average price is $92.20.

West Pharmaceutical Services (NYSE:WST) last posted its earnings results on Thursday, October 26th. The medical instruments supplier reported $0.67 earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of $0.53 by $0.14. West Pharmaceutical Services had a return on equity of 14.90% and a net margin of 12.12%. The firm had revenue of $398.20 million for the quarter, compared to analyst estimates of $386.02 million. During the same quarter in the prior year, the company earned $0.53 EPS. West Pharmaceutical Services’s revenue was up 5.7% on a year-over-year basis. Equities analysts forecast that West Pharmaceutical Services will post $2.71 earnings per share for the current year.

WARNING: This piece was reported by Community Financial News and is the sole property of of Community Financial News. If you are viewing this piece on another publication, it was stolen and republished in violation of US and international copyright law. The correct version of this piece can be read at https://www.com-unik.info/2017/10/30/wells-fargo-company-raises-west-pharmaceutical-services-inc-wst-price-target-to-112-00.html.

Several institutional investors have recently modified their holdings of WST. Acrospire Investment Management LLC purchased a new position in shares of West Pharmaceutical Services during the 2nd quarter worth $113,000. Citigroup Inc. lifted its stake in shares of West Pharmaceutical Services by 95.1% during the 2nd quarter. Citigroup Inc. now owns 1,569 shares of the medical instruments supplier’s stock worth $148,000 after purchasing an additional 765 shares during the period. Wolverine Trading LLC purchased a new position in shares of West Pharmaceutical Services during the 2nd quarter worth $200,000. Nomura Holdings Inc. purchased a new position in shares of West Pharmaceutical Services during the 2nd quarter worth $201,000. Finally, Cambridge Investment Research Advisors Inc. lifted its stake in shares of West Pharmaceutical Services by 1.6% during the 1st quarter. Cambridge Investment Research Advisors Inc. now owns 2,569 shares of the medical instruments supplier’s stock worth $210,000 after purchasing an additional 40 shares during the period. 90.17% of the stock is currently owned by institutional investors.

West Pharmaceutical Services Company Profile

West Pharmaceutical Services, Inc is a manufacturer of packaging components and delivery systems for injectable drugs and healthcare products. The Company’s products include vial containment solutions, prefillable systems, self-injection platforms, cartridge systems and components, reconstitution and transfer systems, intradermal delivery solutions, specialty components, and contract manufacturing and analytical services.

Analyst Recommendations for West Pharmaceutical Services (NYSE:WST)

What are top analysts saying about West Pharmaceutical Services Inc.? - Enter your email address in the form below to receive our free daily email newsletter that contains the latest headlines and analysts' recommendations for for West Pharmaceutical Services Inc. and related companies.

Comments

Leave a Reply


share news on Facebook
tweet this investment news
share on linkedin
share on StockTwits
share on Google Plus
share on reddit